AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

AKTX · NASDAQ · Biotechnology

Akari Therapeutics (ADR) (AKTX)

Develops preclinical oncology antibody-drug conjugates based on its PH1 payload platform.

$10.02

Pre-market−0.13 (−1.28%)

At close$10.15(−2.12%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Institutions6 holders · as of Mar 31, 2026	5.83%	66.7K ADS
Insiders2 holders · as of Aug 19, 2026	2.13%	24.4K ADS
Otherremainder	92.04%	1.05M ADS

1.14M ADS as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

The share count has not been confirmed by a second filing; stakes use it as it stands.

Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.

A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Armistice Capital, LLCInstitution	3.40%	38,922 ADS	13Fas of Mar 31, 2026
Kameel D. FaragInsiderofficer: Interim CFO	2.04%	23,309 ADS	Form 4filed Aug 19, 2026 ↗
Cresset Asset Management, LLCInstitution	1.80%	20,561 ADS	13Fas of Mar 31, 2026
Ifp Advisors, IncInstitution	0.63%	7,250 ADS	13Fas of Mar 31, 2026
Robert B. BazemoreInsiderdirector	0.10%	1,116 ADS	Form 4filed Mar 10, 2025 ↗
Sbi Securities Co., Ltd.Institution	0.00%	5 ADS	13Fas of Mar 31, 2026
Morgan StanleyInstitution	0.00%	1 ADS	13Fas of Mar 31, 2026
Truvestments Capital LLCInstitution	0.00%	1 ADS	13Fas of Mar 31, 2026
Bank of MontrealStrategic	—5.71% of class, as filed	—	13Gfiled Aug 12, 2026 ↗
Charles Steve Theofilos, M.D.Insider	—9.99% of class, as filed	—	13Dfiled Jun 18, 2024 ↗
Wendy F. Dicicco¹Insiderofficer: Interim CFO	—	—	Form 4filed May 3, 2024 ↗
Deerfield Management Company, L.P.Institution	—2.12% of class, as filed	—	13G/Afiled Feb 14, 2018 ↗
Abizer Gaslightwala¹Insiderdirector, officer: CEO	—	—	Form 4filed Aug 29, 2025 ↗
Torsten Hombeck¹Insiderofficer: CFO	—	—	Form 4filed Jan 13, 2025 ↗
Hoyoung Huh¹Insiderdirector, 10 percent owner	—18.40% of class, as filed	—	13Gfiled Mar 4, 2026 ↗
Rachelle Suzanne Jacques¹Insiderdirector, officer: Chief Executive Officer	—	—	Form 4filed Apr 30, 2024 ↗
MMCAP International Inc. SPCStrategic	—8.00% of class, as filed	—	13Gfiled Jun 8, 2026 ↗
James R. Neal¹Insiderdirector	—	—	Form 4filed Mar 10, 2025 ↗
Partners, LLCStrategic	—19.89% of class, as filed	—	13Gfiled Jul 2, 2020 ↗
Samir Rashmikant Patel¹Insiderdirector, 10 percent owner	—	—	Form 4filed Jul 17, 2026 ↗
Sandip I. Patel¹Insiderdirector	—	—	Form 4filed Apr 29, 2025 ↗
Raymond Prudo-Chlebosz¹Insiderdirector	—	—	Form 4filed Mar 10, 2025 ↗
Ray Prudo, M.D.Insider	—8.90% of class, as filed	—	13Dfiled Mar 4, 2026 ↗
Samir R. PatelInsider	—10.40% of class, as filed	—	13Dfiled Mar 4, 2026 ↗
Donald A. Williams¹Insiderdirector	—	—	Form 4filed Jan 2, 2024 ↗

This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

6 holders · 66.7K shares

Holder	Shares	% outstanding	Filed
Armistice Capital, LLC	38.9K	3.40%	May 15, 2026
Cresset Asset Management, LLC	20.6K	1.80%	May 15, 2026
Ifp Advisors, Inc	7.3K	0.63%	Apr 13, 2026
Sbi Securities Co., Ltd.	5	0.00%	Apr 28, 2026
Truvestments Capital LLC	1	0.00%	May 13, 2026
Morgan Stanley	1	0.00%	May 15, 2026

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Form	Filed
Hoyoung Huh, M.D., Ph.D.	18.40%	13G	Mar 4, 2026 ↗
Samir R. Patel	10.40%	13D	Mar 4, 2026 ↗
Ray Prudo, M.D.incl. Praxis Trustees Limited as trustee of the Sonic Healthcare Holding Company, RPC Pharma Limited	8.90%	13D	Mar 4, 2026 ↗
MMCAP International Inc. SPC	8.00%	13G	Jun 8, 2026 ↗
Bank of Montreal	5.71%	13G	Aug 12, 2026 ↗
White Lion Capital LLC	5.00%	13G	Aug 7, 2026 ↗

Insider tradesForm 4

Latest trades

Date	Insider	Type	Shares	Avg price	Owned after
Dec 16, 2025	James R. Nealdirector	Purchase · 4 lots	11,132	$0.3883	8,659
Dec 16, 2025	Robert B. Bazemoredirector	Purchase · 4 lots	309,326	$0.3883	278,394
Dec 16, 2025	Abizer Gaslightwaladirector, officer: CEO	Purchase · 4 lots	2,165,302	$0.3883	1,855,974
Dec 16, 2025	Samir Rashmikant Pateldirector, 10 percent owner:	Purchase · 4 lots	1,701,310	$0.3883	1,701,310
Dec 16, 2025	Kameel D. Faragofficer: Interim CFO	Purchase · 2 lots	49,490	$0.3883	49,490
Dec 16, 2025	Hoyoung Huhdirector, 10 percent owner:	Purchase · 4 lots	7,423,902	$0.3883	6,805,244
Dec 16, 2025	Sandip I. Pateldirector	Purchase · 4 lots	804,252	$0.3883	649,588
Dec 16, 2025	Raymond Prudo-Chleboszdirector	Purchase · 4 lots	2,010,638	$0.3883	1,623,977

CongressHouse and Senate disclosures

Not reported.